SCHEMBL4492204

SCHEMBL4492204

O=C(O)c1ccc2c(c1)ncn2-c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.57
HPGD P15428 3/20 0.56
MRGPRX4 Q96LA9 1/20 0.56
THRB P10828 1/20 0.55
MAOB P27338 2/20 0.53
PPARA Q07869 1/20 0.53
NR4A2 P43354 2/20 0.50
GSK3B P49841 1/20 0.50
RXRA P19793 2/20 0.48
RXRB P28702 2/20 0.48
TSHR P16473 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
RIPK1 Q13546 1/20 0.47
RIPK3 Q9Y572 1/20 0.47
SLC6A5 Q9Y345 1/20 0.47
KDM5A P29375 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
RXRG P48443 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4492465 0.91 FGFR1 (0.56) FGFR1HPGDMRGPRX4THRBGSK3B
SCHEMBL1381279 0.91 MAOB (0.64) FGFR1HPGDMAOBGSK3BRIPK1
SCHEMBL1380812 0.88 RIPK1 (0.63) FGFR1HPGDMAOBGSK3BRIPK1
SCHEMBL121458 0.88 FGFR1 (0.72) FGFR1HPGDTHRBGSK3BTSHR
SCHEMBL1383460 0.86 HPGD (0.53) FGFR1HPGDMAOBGSK3BRIPK1
SCHEMBL1380412 0.86 MEN1 (0.55) HPGDMAOBRIPK1RIPK3SLC6A5
SCHEMBL1379760 0.84 HPGD (0.64) HPGDMAOBGSK3BRIPK1RIPK3
SCHEMBL1378802 0.81 HPGD (0.54) HPGDSLC6A5
SCHEMBL24074851 0.81 SMPD1 (0.51) FGFR1HPGDMAOBPPARASLC6A5
SCHEMBL4501197 0.81 FGFR1 (0.60) FGFR1HPGDMRGPRX4GSK3BRIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521448-B2 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US disclosed
EP-1664021-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-06-07 EP disclosed
WO-2005021531-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors KIT, CHUK, TNNI3K FGFR1 912/4885HPGD 1154/4885MRGPRX4 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.